RTP Mobile Logo
Dissecting the Decision: Investigators Discuss the Available Data and Clinical Factors That Shape the Management of Gastrointestinal Cancers
Released March 2017

Faculty presentations from a CME symposium held at the 2017 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Tanios Bekaii-Saab, Johanna C Bendell, John L Marshall, Bert H O’Neil, Philip A Philip and Eric Van Cutsem. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

    OVERVIEW OF ACTIVITY
    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other “non-CRC” GI cancers account for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. As such, educational opportunities relevant to the clinical management of both CRC and non-CRC GI tumors are essential to the general oncologist’s delivery of comprehensive cancer care.

    These video highlights from a CME symposium held during the 2017 Gastrointestinal Cancers Symposium feature presentations given by leading investigators in the management of GI cancers. By providing information on important new developments, this activity will address the most pressing educational needs of practitioners involved in the multidisciplinary management of colorectal, gastric, pancreatic and hepatocellular cancer.

    LEARNING OBJECTIVES

    • Appraise recent data on therapeutic advances and changing practice standards in colorectal, gastric, pancreatic and hepatocellular cancer, and integrate this information, as appropriate, into current clinical care.
    • Develop a long-term care plan for individuals with metastatic CRC considering biomarker profile, exposure to prior systemic therapy, symptomatology, performance status and personal goals for treatment.
    • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for patients with locally advanced or metastatic gastric or gastroesophageal cancer.
    • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with locally advanced or metastatic pancreatic cancer.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular cancer.
    • Communicate with patients and their caregivers regarding the incidence and manifestation of side effects and toxicities associated with commonly used systemic agents and regimens in the management of advanced colorectal, gastric, pancreatic and hepatocellular cancer.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies for patients with GI cancers.
    • Describe the proposed mechanisms of action of and recall new data with investigational agents demonstrating promising activity in colorectal, gastric, pancreatic and hepatocellular cancer, and use this information to counsel appropriate patients regarding participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GICancers17/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Co-Leader, GI Cancer Program
    Mayo Clinic Cancer Center
    Senior Associate Consultant
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Merck, Taiho Oncology Inc; Data and Safety Monitoring Board: Exelixis Inc, Silagen.

    Johanna C Bendell, MD
    Director, GI Oncology Research
    Associate Director, Drug Development Unit
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Contracted Research: Abbott Laboratories, AbbVie Inc, Apexigen, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Five Prime Therapeutics Inc, Forty Seven Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Stemcentrx, Taiho Oncology Inc, Takeda Oncology, TG Therapeutics Inc.

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, Genentech BioOncology, Lilly.

    Bert H O’Neil, MD
    Professor of Medicine
    Director, Phase I and GI Malignancies Programs
    Indiana University Simon Cancer Center
    Indianapolis, Indiana

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology; Speakers Bureau: Bayer HealthCare Pharmaceuticals.

    Philip A Philip, MD, PhD
    Professor of Oncology and Medicine
    Director of GI and Neuroendocrine Tumors
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, Michigan

    Advisory Committee: bioTheranostics Inc, Caris Life Sciences, Celgene Corporation, EMD Serono Inc, Halozyme Inc, Lexicon Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc; Contracted Research: Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Taiho Oncology Inc, XBiotech; Speakers Bureau: Amgen Inc, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospital Gasthuisberg/Leuven
    Leuven, Belgium

    Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Ipsen, Lilly, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi Genzyme.

    CONSULTING MEDICAL ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Gigi Chen, MD
    Diablo Valley Oncology and Hematology Medical Group
    Pleasant Hill, California

    Advisory Committee: Bayer HealthCare Pharmaceuticals; Speakers Bureau: Boehringer Ingelheim Pharmaceuticals Inc.

    Paul Fishkin, MD
    Illinois CancerCare
    Peoria, Illinois

    Advisory Board: AbbVie Inc; Stock Ownership: Biogen, Novartis Pharmaceuticals Corporation.

    Sulfi Ibrahim, MD
    Indiana University Health
    Ball Memorial Hospital
    Muncie, Indiana

    No relevant conflicts of interest to disclose.

    Nishi Kothari, MD
    Tampa, Florida

    No relevant conflicts of interest to disclose.

    John Leighton, MD
    Thomas Jefferson University
    Philadelphia, Pennsylvania

    Contracted Research: XBiotech.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Halozyme Inc, Lilly, Merrimack Pharmaceuticals Inc and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2017
    Expiration date: March 2018

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Topics:

Dr Philip — Presentation

  • Important Systemic Treatment Considerations for Patients with Pancreatic Adenocarcinoma

Dr Bekaii-Saab — Presentation

  • Current and Future Treatment of Gastric and Gastroesophageal Cancer

Dr O’Neil — Presentation

  • Systemic Therapy in the Multidisciplinary Management of Hepatocellular Carcinoma; Novel Agents and Strategies

Dr Marshsall — Presentation

  • Biologic and Clinical Factors in the Selection and Sequencing of Systemic Therapy for Patients with Metastatic Colorectal Cancer

Prof Van Cutsem — Presentation

  • Later-Line Management of Progressive Metastatic Colorectal Cancer

Dr Bendell — Presentation

  • Checkpoint Inhibitors in the Treatment of Metastatic Colorectal Cancer